PROTACs

PROteolysis TArgeting Chimeras (PROTACs) achieve degradation through "hijacking" the cell's ubiquitin–proteasome system (UPS) by bringing together the target protein and an E3 ligase. Because PROTACs need only to bind their targets with high selectivity (rather than inhibit the target protein's enzymatic activity), there are currently many efforts to retool previously ineffective inhibitor molecules as PROTACs for next-generation drugs.

Cat. No.	Product name	CAS No.	Purity
T14908	CCT367766	2229856-58-8	100%
T14908	CCT367766 is a potent, PROTAC-based, third-generation, iso-functional pirin-targeted protein degradation probe (PDP) that depletes pirin expression at low concen...
T77913	PZ703b TFA		98%
T77913	PZ703b TFA, a Bcl-xl PROTAC degradation agent, promotes apoptosis and halts bladder cancer cell proliferation, making it a pertinent investigative compound for r...
T77915	CCT367766 formic		98%
T77915	CCT367766 formic is a potent third-generation heterobifunctional Cereblon-based protein degradation probe (PDP, or PROTAC) that selectively targets pirin for deg...
T77920	ZXH-4-130 TFA	2711006-67-4	98%
T77920	ZXH-4-130 TFA is a hetero-PROTAC (CRBN-VHL compound) that efficaciously and selectively mediates the degradation of CRBN. At a concentration of 10 nM in MM1.S ce...
T77922	HDAC6 degrader-1	2439058-23-6	98%
T77922	HDAC6 degrader-1, a proteolysis-targeting chimeric molecule (PROTAC), incorporates the selective HDAC6 inhibitor Nexturastat A (Nex A) for HDAC6 binding, a linke...
T77924	SB1-G-187	2769753-18-4	98%
T77924	SB1-G-187 is a PROTAC (PROteolysis TArgeting Chimera) that functions as a multi-kinase degrader [1].
T77925	DB-0646		98%
T77925	DB-0646 is a PROTAC designed to induce the degradation of multiple kinases.
T77926	PROTAC KRAS G12C degrader-1		98%
T77926	PROTAC KRAS G12C degrader-1, a cereblon-based degrader, promotes CRBN/KRAS G12C dimerization and facilitates the degradation of GFP-KRAS G12C in reporter cells [...
T77929	Dovitinib-RIBOTAC	2759351-68-1	98%
T77929	Dovitinib RIBOTAC is a potent, selective targeted RNA degrader that cleaves pre-miR-21.
T77930	Dovitinib-RIBOTAC TFA	2759351-69-2	98%
T77930	Dovitinib RIBOTAC TFA effectively and selectively cleaves pre-miR-21, functioning as a targeted RNA degrader.
T77931	PROTAC IRAK3 degrade-1 formic		98%
T77931	PROTAC IRAK3 Degrade-1 (Compound 23) is a selective and potent IRAK3 degrader, demonstrating an IC50 value of 5 nM [1].
T77932	PF15 TFA		98%
T77932	PF15 TFA, a PROTAC targeting FLT3 kinase and CRBN, exhibits selective degradation of FLT3-ITD with a DC50 of 76.7 nM. The compound potently suppresses proliferat...
T77933	SJ995973	2882065-25-8	98%
T77933	SJ995973 (PROTAC) represents a highly efficacious degrader of bromodomain and extra-terminal (BET) proteins.
T77934	PhosTAC7		98%
T77934	PhosTAC7, akin to PROTACs in promoting ternary complex formation, recruits a Ser/Thr phosphatase to a phosphosubstrate to facilitate dephosphorylation.
T77936	PROTAC BRD9 Degrader-4	2633632-34-3	98%
T77936	PROTAC BRD9 Degrader-4 is a bifunctional degrader targeting BRD9, designed for cancer research applications.
T77942	SIAIS164018 hydrochloride		98%
T77942	SIAIS164018 hydrochloride is a PROTAC-based degrader targeting ALK and EGFR, exhibiting IC50 values of 2.5 nM for ALK and 6.6 nM for ALK G1202R. It effectively s...
T77944	SJ1008030 formic		98%
T77944	SJ1008030 (compound 8) formic is a selective JAK2 degrader within the PROTAC class, demonstrating efficacy in inhibiting MHH-CALL-4 leukemia cell growth with an ...
T77948	Tri-GalNAc-DBCO		98%
T77948	Tri-GalNAc-DBCO, a compound with high affinity for the hepatocyte-specific asialoglycoprotein receptor (ASGPR), can bind to this receptor, facilitating targeted ...
T77967	MS159		98%
T77967	MS159 is a potent PROTAC degrader targeting the nuclear receptor binding SET structural domain protein 2 (NSD2), which inhibits tumor cell growth. This compound ...
T77968	MS15 TFA		98%
T77968	MS15 TFA is a potent, selective AKT PROTAC degrader, effectively inhibiting AKT1, AKT2, and AKT3 with IC50 values of 798 nM, 90 nM, and 544 nM, respectively [1]....